<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FLUDARABINE PHOSPHATE- fludarabine phosphate injection, powder, lyophilized, for solution </strong><br>Sagent Pharmaceuticals<br></p></div>
<h1>Fludarabine Phosphate for Injection, USP<br>(For Intravenous Use Only)
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First">SAGENT™<br>Rx only
</p>
</div>
<div class="Warning">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>WARNING
</h1>
<p class="First">Fludarabine phosphate for injection should be administered under the supervision of a qualified physician experienced in the use of antineoplastic therapy. Fludarabine phosphate for injection can severely suppress bone marrow function. When used at high doses in dose-ranging studies in patients with <span class="product-label-link" type="condition" conceptid="138708" conceptname="Acute leukemia">acute leukemia</span>, fludarabine phosphate for injection was associated with severe neurologic effects, including <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. This severe central nervous system toxicity occurred in 36% of patients treated with doses approximately four times greater (96 mg/m<span class="Sup">2</span>/day for 5 to 7 days) than the recommended dose. Similar severe central nervous system toxicity, including <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, has been reported in patients treated at doses in the range of the dose recommended for <span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">chronic lymphocytic leukemia</span>.
</p>
<p>Instances of life-threatening and sometimes fatal autoimmune phenomena such as <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="4028065" conceptname="Autoimmune thrombocytopenia">autoimmune thrombocytopenia</span>/<span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span> (ITP), <span class="product-label-link" type="condition" conceptid="436956" conceptname="Evans syndrome">Evans syndrome</span>, and acquired <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> have been reported to occur after one or more cycles of treatment with fludarabine phosphate for injection. Patients undergoing treatment with fludarabine phosphate for injection should be evaluated and closely monitored for <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>.
</p>
<p>In a clinical investigation using fludarabine phosphate for injection in combination with pentostatin (deoxycoformycin) for the treatment of refractory <span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">chronic lymphocytic leukemia</span> (CLL), there was an unacceptably high incidence of fatal pulmonary toxicity. Therefore, the use of fludarabine phosphate for injection in combination with pentostatin is not recommended.
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s3"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION
</h1>
<p class="First">Fludarabine Phosphate for Injection, USP contains fludarabine phosphate, a fluorinated nucleotide analog of the antiviral agent vidarabine, 9-β-D-arabinofuranosyladenine (ara-A) that is relatively resistant to deamination by adenosine deaminase. Each vial of sterile lyophilized solid cake contains 50 mg of the active ingredient fludarabine phosphate, USP, 50 mg of mannitol, USP, and sodium hydroxide to adjust pH to 7.7. The pH range for the final product is 7.2 to 8.2. Reconstitution with 2 mL of Sterile Water for Injection, USP results in a solution containing 25 mg per mL of fludarabine phosphate, USP, intended for intravenous administration.
</p>
<p>The chemical name for fludarabine phosphate, USP is 9<span class="Underline">H</span>-Purin-6-amine, 2-fluoro-9-(5-<span class="Underline">0</span>-phosphono-β-D-arabino-furanosyl) (2-fluoro-ara-AMP). The molecular formula of fludarabine phosphate, USP is C<span class="Sub">10</span>H<span class="Sub">13</span>FN<span class="Sub">5</span>O<span class="Sub">7</span>P (MW 365.2) and the structure is:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Chemical Structure
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=763d6c6d-cfed-4813-8cc5-41e78d357845&amp;name=flu15-0000-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s4"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<p class="First">Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis. The mechanism of action of this antimetabolite is not completely characterized and may be multi-faceted.
</p>
<p>Phase I studies in humans have demonstrated that fludarabine phosphate is rapidly converted to the active metabolite, 2-fluoro-ara-A, within minutes after intravenous infusion. Consequently, clinical pharmacology studies have focused on 2-fluoro-ara-A pharmacokinetics. After the five daily doses of 25 mg 2-fluoro-ara-AMP/m<span class="Sup">2</span> to cancer patients infused over 30 minutes, 2-fluoro-ara-A concentrations show a moderate accumulation. During a 5-day treatment schedule, 2-fluoro-ara-A plasma trough levels increased by a factor of about 2. The terminal half-life of 2-fluoro-ara-A was estimated as approximately 20 hours. <span class="Italics">In vitro</span>, plasma protein binding of fludarabine ranged between 19% and 29%.
</p>
<p>A correlation was noted between the degree of absolute granulocyte count nadir and increased area under the concentration x time curve (AUC).
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-3.1"></a><p></p>
<h2>Special Populations
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-3.1.1"></a><p></p>
<h3>Pediatric Patients
</h3>
<p class="First">Limited pharmacokinetic data for fludarabine phosphate for injection are available from a published study of children (ages 1 to 21 years) with refractory <span class="product-label-link" type="condition" conceptid="138708" conceptname="Acute leukemia">acute leukemias</span> or <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span> (Children's Cancer Group Study 097<span class="Sup">1</span>). When fludarabine phosphate for injection was administered as a loading dose over 10 minutes immediately followed by a 5-day continuous infusion, steady-state conditions were reached early.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-3.1.2"></a><p></p>
<h3>Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h3>
<p class="First">The total body clearance of the principal metabolite 2-fluoro-ara-A correlated with the creatinine clearance, indicating the importance of the renal excretion pathway for the elimination of the drug. Renal clearance represents approximately 40% of the total body clearance. Patients with creatinine clearance 30 to 79 mL/min should have their fludarabine dose reduced and be monitored closely for excessive toxicity. Due to insufficient data, fludarabine phosphate for injection should not be administered to patients with creatinine clearance less than 30 mL/min. (See <span class="Bold"><a href="#s47">DOSAGE AND ADMINISTRATION</a></span> section.)
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s8"></a><a name="section-4"></a><p></p>
<h1>CLINICAL STUDIES
</h1>
<p class="First">Two single-arm open-label studies of fludarabine phosphate for injection have been conducted in adult patients with CLL refractory to at least one prior standard alkylating-agent containing regimen. In a study conducted by M.D. Anderson Cancer Center (MDAH), 48 patients were treated with a dose of 22 to 40 mg/m<span class="Sup">2</span> daily for 5 days every 28 days. Another study conducted by the Southwest Oncology Group (SWOG) involved 31 patients treated with a dose of 15 to 25 mg/m<span class="Sup">2</span> daily for 5 days every 28 days. The overall objective response rates were 48% and 32% in the MDAH and SWOG studies, respectively. The complete response rate in both studies was 13%; the partial response rate was 35% in the MDAH study and 19% in the SWOG study. These response rates were obtained using standardized response criteria developed by the National Cancer Institute CLL Working Group<span class="Sup">3</span> and were achieved in heavily pretreated patients. The ability of fludarabine phosphate for injection to induce a significant rate of response in refractory patients suggests minimal cross-resistance with commonly used anti-CLL agents.
</p>
<p>The median time to response in the MDAH and SWOG studies was 7 weeks (range of 1 to 68 weeks) and 21 weeks (range of 1 to 53 weeks) respectively. The median duration of disease control was 91 weeks (MDAH) and 65 weeks (SWOG). The median survival of all refractory CLL patients treated with fludarabine phosphate for injection was 43 weeks and 52 weeks in the MDAH and SWOG studies, respectively.
</p>
<p>Rai stage improved to Stage II or better in 7 of 12 MDAH responders (58%) and in 5 of 7 SWOG responders (71%) who were Stage III or IV at baseline. In the combined studies, mean hemoglobin concentration improved from 9.0 g/dL at baseline to 11.8 g/dL at the time of response in a subgroup of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemic</span> patients. Similarly, average platelet count improved from 63,500/mm<span class="Sup">3</span> to 103,300/mm<span class="Sup">3</span> at the time of response in a subgroup of patients who were thrombocytopenic at baseline.
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s9"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<p class="First">Fludarabine Phosphate for Injection, USP is indicated for the treatment of adult patients with B-cell <span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">chronic lymphocytic leukemia</span> (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen. The safety and effectiveness of Fludarabine Phosphate for Injection, USP in previously untreated or non-refractory patients with CLL have not been established.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s10"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First">Fludarabine phosphate for injection is contraindicated in those patients who are hypersensitive to this drug or its components.
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s11"></a><a name="section-7"></a><p></p>
<h1>WARNINGS
</h1>
<p class="First">(See <span class="Bold"><a href="#s2">BOXED WARNINGS</a>.</span>)
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-7.1"></a><p></p>
<h2>Dose Dependent Neurologic Toxicities
</h2>
<p class="First">There are clear dose dependent toxic effects seen with fludarabine phosphate for injection. Dose levels approximately 4 times greater (96 mg/m<span class="Sup">2</span>/day for 5 to 7 days) than that recommended for CLL (25 mg/m<span class="Sup">2</span>/day for 5 days) were associated with a syndrome characterized by delayed <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Symptoms appeared from 21 to 60 days following the last dose. Thirteen of 36 patients (36%) who received fludarabine phosphate for injection at high doses (96 mg/m<span class="Sup">2</span>/day for 5 to 7 days) developed this severe <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>. Similar severe central nervous system toxicity, including <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, has been reported in patients treated at doses in the range of the dose recommended for <span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">chronic lymphocytic leukemia</span>.
</p>
<p>In postmarketing experience <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> has been reported to occur either earlier or later than in clinical trials (range 7 to 225 days).  
</p>
<p>The effect of chronic administration of fludarabine phosphate for injection on the central nervous system is unknown; however, patients have received the recommended dose for up to 15 courses of therapy.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-7.2"></a><p></p>
<h2>Bone Marrow Suppression
</h2>
<p class="First">Severe bone marrow suppression, notably <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, has been reported in patients treated with fludarabine phosphate for injection. In a Phase I study in adult <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumor</span> patients, the median time to nadir counts was 13 days (range, 3 to 25 days) for granulocytes and 16 days (range, 2 to 32) for platelets. Most patients had hematologic impairment at baseline either as a result of disease or as a result of prior myelosuppressive therapy. Cumulative <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> may be seen. While chemotherapy-induced <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> is often reversible, administration of fludarabine phosphate for injection requires careful hematologic monitoring.
</p>
<p>Several instances of trilineage bone <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">marrow hypoplasia</span> or <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span> resulting in <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, sometimes resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have been reported in adult patients. The duration of clinically significant <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenia</span> in the reported cases has ranged from approximately 2 months to approximately 1 year. These episodes have occurred both in previously treated or untreated patients.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-7.3"></a><p></p>
<h2>Autoimmune Reactions
</h2>
<p class="First">Instances of life-threatening and sometimes fatal autoimmune phenomena such as <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="4028065" conceptname="Autoimmune thrombocytopenia">autoimmune thrombocytopenia</span>/<span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span> (ITP), <span class="product-label-link" type="condition" conceptid="436956" conceptname="Evans syndrome">Evans syndrome</span>, and acquired <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> have been reported to occur after one or more cycles of treatment with fludarabine phosphate for injection in patients with or without a previous history of <span class="product-label-link" type="condition" conceptid="441269" conceptname="Autoimmune hemolytic anemia">autoimmune hemolytic anemia</span> or a positive Coombs' test and who may or may not be in remission from their disease. Steroids may or may not be effective in controlling these hemolytic episodes. The majority of patients rechallenged with fludarabine phosphate for injection developed a recurrence in the hemolytic process. The mechanism(s) which predispose patients to the development of this complication has not been identified. Patients undergoing treatment with fludarabine phosphate for injection should be evaluated and closely monitored for <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>. Discontinuation of therapy with fludarabine is recommended in case of <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-7.4"></a><p></p>
<h2>Transfusion Associated Graft-Versus-Host Disease
</h2>
<p class="First">Transfusion-associated graft-versus-host disease has been observed after transfusion of nonirradiated blood in fludarabine phosphate for injection treated patients. Fatal outcome as a consequence of this disease has been reported. Therefore, to minimize the risk of transfusion-associated graft-versus-host disease, patients who require blood transfusion and who are undergoing, or who have received, treatment with fludarabine phosphate for injection should receive irradiated blood only.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-7.5"></a><p></p>
<h2>Pulmonary Toxicity
</h2>
<p class="First">In a clinical investigation using fludarabine phosphate for injection in combination with pentostatin (deoxycoformycin) for the treatment of refractory <span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">chronic lymphocytic leukemia</span> (CLL) in adults, there was an unacceptably high incidence of fatal pulmonary toxicity. Therefore, the use of fludarabine phosphate for injection in combination with pentostatin is not recommended.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-7.6"></a><p></p>
<h2>Pregnancy Category D
</h2>
<p class="First">Based on its mechanism of action, fludarabine phosphate can cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies of fludarabine phosphate for injection in pregnant women. Fludarabine administered to rats and rabbits during organogenesis caused an increase in resorptions, skeletal and visceral malformations and decreased fetal body weights. If fludarabine phosphate for injection is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-7.7"></a><p></p>
<h2>Male Fertility and Reproductive Outcomes  
</h2>
<p class="First">Males with female sexual partners of childbearing potential should use contraception during and after cessation of fludarabine phosphate for injection therapy. Fludarabine may damage testicular tissue and spermatozoa. Possible sperm DNA damage raises concerns about loss of fertility and genetic abnormalities in fetuses. The duration of this effect is uncertain. (See <span class="Bold"><a href="#s26">PRECAUTIONS, Impairment of Fertility</a>.</span>)
</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s19"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s20"></a><a name="section-8.1"></a><p></p>
<h2>General
</h2>
<p class="First">Fludarabine phosphate for injection is a potent antineoplastic agent with potentially significant toxic side effects. Patients undergoing therapy should be closely observed for signs of hematologic and nonhematologic toxicity. Periodic assessment of peripheral blood counts is recommended to detect the development of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.
</p>
<p>In patients with impaired state of health, fludarabine phosphate for injection should be given with caution and after careful risk/benefit consideration. This applies especially for patients with severe impairment of bone marrow function (<span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, and/or <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>), <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> or with a history of <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infection</span>. <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> treatment should be considered in patients at increased risk of developing <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>.
</p>
<p>Fludarabine phosphate for injection may reduce the ability to drive or use machines, since <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> have been observed.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-8.2"></a><p></p>
<h2>Tumor Cell Lysis
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor lysis syndrome</span> has been associated with fludarabine phosphate for injection treatment. This syndrome has been reported in CLL patients with large tumor burden. Since fludarabine phosphate for injection can induce a response as early as the first week of treatment, precautions should be taken in those patients at risk of developing this complication.
</p>
<p><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</p>
<p>Fludarabine phosphate for injection must be administered cautiously in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. The total body clearance of 2-fluoro-ara-A has been shown to be directly correlated with creatinine clearance.  Patients with creatinine clearance 30 to 79 mL/min should have their fludarabine phosphate for injection dose reduced and be monitored closely for excessive toxicity. Fludarabine phosphate for injection should not be administered to patients with creatinine clearance less than 30 mL/min. (See <span class="Bold"><a href="#s47">DOSAGE AND ADMINISTRATION</a></span> section.)
</p>
<p>In patients aged 65 years or older, creatinine clearance should be measured before start of treatment.
</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="s22"></a><a name="section-8.3"></a><p></p>
<h2>Laboratory Tests
</h2>
<p class="First">During treatment, the patient's hematologic profile (particularly <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> and platelets) should be monitored regularly to determine the degree of hematopoietic suppression.
</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s23"></a><a name="section-8.4"></a><p></p>
<h2>Drug Interactions
</h2>
<p class="First">The use of fludarabine phosphate for injection in combination with pentostatin is not recommended due to the risk of fatal pulmonary toxicity (see <span class="Bold"><a href="#s11">WARNINGS</a></span> section).
</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s24"></a><a name="section-8.5"></a><p></p>
<h2>Carcinogenesis
</h2>
<p class="First">No animal carcinogenicity studies with fludarabine phosphate for injection have been conducted.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-8.6"></a><p></p>
<h2>Mutagenesis
</h2>
<p class="First">Fludarabine phosphate was not mutagenic to bacteria (Ames test) or mammalian cells (HGRPT assay in Chinese hamster ovary cells) either in the presence or absence of metabolic activation. Fludarabine phosphate was clastogenic <span class="Italics">in vitro</span> to Chinese hamster ovary cells (chromosome aberrations in the presence of metabolic activation) and induced sister chromatid exchanges both with and without metabolic activation. In addition, fludarabine phosphate was clastogenic <span class="Italics">in vivo</span> (mouse micronucleus assay) but was not mutagenic to germ cells (dominant lethal test in male mice).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-8.7"></a><p></p>
<h2>Impairment of Fertility
</h2>
<p class="First">Studies in mice, rats and dogs have demonstrated dose-related adverse effects on the male reproductive system. Observations consisted of a decrease in mean testicular weights in mice and rats with a trend toward decreased testicular weights in dogs and degeneration and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> of spermatogenic epithelium of the testes in mice, rats and dogs. The possible adverse effects on fertility in humans have not been adequately evaluated.
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s27"></a><a name="section-8.8"></a><p></p>
<h2>Pregnancy
</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s28"></a><a name="section-8.8.1"></a><p></p>
<h3>Teratogenic Effects
</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-8.8.1.1"></a><p></p>
<h4>Pregnancy Category D
</h4>
<p class="First">(See <span class="Bold"><a href="#s11">WARNINGS</a></span> section.)
</p>
<p>Based on its mechanism of action, fludarabine phosphate can cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies of fludarabine phosphate in pregnant women. Fludarabine phosphate was embryolethal and teratogenic in rats and rabbits. If fludarabine phosphate for injection is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.
</p>
<p>In rats, repeated intravenous doses of fludarabine phosphate at 2.4 times and 7.2 times the recommended human IV dose (25 mg/m<span class="Sup">2</span>) administered during organogenesis caused an increase in resorptions, skeletal and visceral malformations (<span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, <span class="product-label-link" type="condition" conceptid="4309376" conceptname="Exencephaly">exencephaly</span>, and fetal vertebrae deformities) and decreased fetal body weights. Maternal toxicity was not apparent at 2.4 times the human IV dose, and was limited to slight body <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decreases</span> at 7.2 times the human IV dose. In rabbits, repeated intravenous doses of fludarabine phosphate at 3.8 times the human IV dose administered during organogenesis increased embryo and fetal lethality as indicated by increased resorptions and a decrease in live fetuses. A significant increase in malformations including <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, <span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">hydrocephaly</span>, <span class="product-label-link" type="condition" conceptid="4169990" conceptname="Adactyly">adactyly</span>, brachydactyly, fusions of the digits, <span class="product-label-link" type="condition" conceptid="201061" conceptname="Diaphragmatic hernia">diaphragmatic hernia</span>, heart/great vessel defects, and vertebrae/rib anomalies were seen in all dose levels (≥ 0.5 times the human IV dose).
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s30"></a><a name="section-8.9"></a><p></p>
<h2>Nursing Mothers
</h2>
<p class="First">It is not known whether fludarabine phosphate is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions including tumorigenicity in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s31"></a><a name="section-8.10"></a><p></p>
<h2>Pediatric Use
</h2>
<p class="First">Data submitted to the FDA was insufficient to establish efficacy in any childhood malignancy. Fludarabine phosphate for injection was evaluated in 62 pediatric patients (median age 10, range 1 to 21) with refractory <span class="product-label-link" type="condition" conceptid="138708" conceptname="Acute leukemia">acute leukemia</span> (45 patients) or <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span> (17 patients). The fludarabine phosphate for injection regimen tested for pediatric <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphocytic leukemia</span> (ALL) patients was a loading bolus of 10.5 mg/m<span class="Sup">2</span>/day followed by a continuous infusion of 30.5 mg/m<span class="Sup">2</span>/day for 5 days. In 12 pediatric patients with <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>, dose-limiting <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> was observed with a loading dose of 8 mg/m<span class="Sup">2</span>/day followed by a continuous infusion of 23.5 mg/m<span class="Sup">2</span>/day for 5 days. The maximum tolerated dose was a loading dose of 7 mg/m<span class="Sup">2</span>/day followed by a continuous infusion of 20 mg/m<span class="Sup">2</span>/day for 5 days. Treatment toxicity included bone marrow suppression. Platelet counts appeared to be more sensitive to the effects of fludarabine phosphate for injection than hemoglobin and white blood cell counts. Other adverse events included <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.  There were no reported occurrences of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> or pulmonary <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-8.11"></a><p></p>
<h2>Vaccination
</h2>
<p class="First">During and after treatment with fludarabine phosphate for injection, vaccination with live vaccines should be avoided.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-8.12"></a><p></p>
<h2>Disease Progression
</h2>
<p class="First">Richter's syndrome has been reported in CLL patients.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s34"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<p class="First">Very common adverse events include <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> (<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Other commonly reported events include <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span> and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>. Serious <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> (such as latent viral reactivation, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> virus, Epstein-Barr virus, and <span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">progressive multifocal leukoencephalopathy</span>) have occurred in CLL patients treated with fludarabine phosphate for injection. Adverse events and those reactions which are more clearly related to the drug are arranged below according to body system.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-9.1"></a><p></p>
<h2>Hematopoietic Systems
</h2>
<p class="First">Hematologic events (<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and/or <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>) were reported in the majority of CLL patients treated with fludarabine phosphate for injection. During fludarabine phosphate for injection treatment of 133 patients with CLL, the absolute neutrophil count decreased to less than 500/mm<span class="Sup">3</span> in 59% of patients, <span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">hemoglobin decreased</span> from pretreatment values by at least 2 grams percent in 60%, and platelet count decreased from pretreatment values by at least 50% in 55%. <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> may be severe, cumulative, and may affect multiple cell lines. Bone marrow <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> occurred in one CLL patient treated with fludarabine phosphate for injection.
</p>
<p>Several instances of trilineage bone <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">marrow hypoplasia</span> or <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span> resulting in <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, sometimes resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have been reported in postmarketing surveillance. The duration of clinically significant <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenia</span> in the reported cases has ranged from approximately 2 months to approximately 1 year. These episodes have occurred both in previously treated or untreated patients.
</p>
<p>Life-threatening and sometimes fatal autoimmune phenomena such as <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="4028065" conceptname="Autoimmune thrombocytopenia">autoimmune thrombocytopenia</span>/<span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span> (ITP), <span class="product-label-link" type="condition" conceptid="436956" conceptname="Evans syndrome">Evans syndrome</span>, and acquired <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> have been reported to occur in patients receiving fludarabine phosphate for injection (see <span class="Bold"><a href="#s11">WARNINGS</a></span> section). The majority of patients rechallenged with fludarabine phosphate for injection developed a recurrence in the hemolytic process.
</p>
<p>In postmarketing experience, cases of <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">myelodysplastic syndrome</span> and <span class="product-label-link" type="condition" conceptid="140352" conceptname="Acute myeloid leukemia, disease">acute myeloid leukemia</span>, mainly associated with prior, concomitant or subsequent treatment with alkylating agents, topoisomerase inhibitors, or irradiation have been reported.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s36"></a><a name="section-9.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>
</h2>
<p class="First">Serious, and sometimes fatal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> and reactivations of latent <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> such as VZV (<span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>), Epstein-Barr virus and JC virus (<span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">progressive multifocal leukoencephalopathy</span>) have been reported in patients treated with fludarabine phosphate for injection.
</p>
<p>Rare cases of Epstein-Barr Virus (EBV) associated <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorders</span> have been reported in patients treated with fludarabine phosphate for injection.
</p>
<p>In postmarketing experience, cases of <span class="product-label-link" type="condition" conceptid="433957" conceptname="Progressive multifocal leukoencephalopathy">progressive multifocal leukoencephalopathy</span> have been reported. Most cases had a fatal outcome. Many of these cases were confounded by prior and/or concurrent chemotherapy. The time to onset has ranged from a few weeks to approximately one year after initiating treatment.
</p>
<p>Of the 133 adult CLL patients in the two trials, there were 29 fatalities during study, approximately 50% of which were due to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-9.3"></a><p></p>
<h2>Metabolic
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor lysis syndrome</span> has been reported in CLL patients treated with fludarabine phosphate for injection. This complication may include <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">urate crystalluria</span>, and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. The onset of this syndrome may be heralded by <span class="product-label-link" type="condition" conceptid="4090433" conceptname="Flank pain">flank pain</span> and <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s38"></a><a name="section-9.4"></a><p></p>
<h2>Nervous System
</h2>
<p class="First">(See <span class="Bold"><a href="#s11">WARNINGS</a></span> section.)
</p>
<p>Objective <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>, <span class="product-label-link" type="condition" conceptid="380410" conceptname="Nutritional optic neuropathy">optic neuropathy</span>, <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> have occurred in CLL patients treated with fludarabine phosphate for injection at the recommended dose. <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span> has been observed in patients treated with fludarabine phosphate for injection and one case of wrist-drop was reported. There have been additional reports of <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">cerebral hemorrhage</span> though the frequency is not known.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s39"></a><a name="section-9.5"></a><p></p>
<h2>Pulmonary System
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>, a frequent manifestation of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in CLL patients, occurred in 16% and 22% of those treated with fludarabine phosphate for injection in the MDAH and SWOG studies, respectively. Pulmonary <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to fludarabine phosphate for injection characterized by <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and interstitial pulmonary infiltrate have been observed.
</p>
<p>In postmarketing experience, cases of severe pulmonary toxicity have been observed with fludarabine phosphate for injection use which resulted in <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="4301606" conceptname="Pulmonary hemorrhage">pulmonary hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span>, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> and <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>. After an infectious origin has been excluded, some patients experienced symptom improvement with corticosteroids.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-9.6"></a><p></p>
<h2>Gastrointestinal System
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disturbances</span> such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> and <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> have been reported in patients treated with fludarabine phosphate for injection. Elevations of pancreatic enzyme levels have also been reported.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s41"></a><a name="section-9.7"></a><p></p>
<h2>Cardiovascular
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> has been frequently reported. One patient developed a <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span> possibly related to treatment with fludarabine phosphate for injection. There have been additional reports of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> though the frequency is rare.  No other severe cardiovascular events were considered to be drug related.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s42"></a><a name="section-9.8"></a><p></p>
<h2>Genitourinary System
</h2>
<p class="First">Rare cases of <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span> have been reported in patients treated with fludarabine phosphate for injection.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s43"></a><a name="section-9.9"></a><p></p>
<h2>Skin
</h2>
<p class="First">Skin toxicity, consisting primarily of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>, has been reported in patients treated with fludarabine phosphate for injection.  <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, and <span class="product-label-link" type="condition" conceptid="135338" conceptname="Pemphigus">pemphigus</span> have been reported, with fatal outcomes in some cases.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-9.10"></a><p></p>
<h2>Neoplasms
</h2>
<p class="First">Worsening or flare up of preexisting skin cancer lesions, as well as new onset of skin cancer, has been reported in patients during or after treatment with fludarabine phosphate for injection.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-9.11"></a><p></p>
<h2>Hepatobiliary Disorders
</h2>
<p class="First">Elevations of hepatic enzyme levels have been reported.
</p>
<p>Data in the following table are derived from the 133 patients with CLL who received fludarabine phosphate for injection in the MDAH and SWOG studies.
</p>
<a name="t300"></a><table width="100%">
<caption><span>PERCENT OF CLL PATIENTS REPORTING NONHEMATOLOGIC ADVERSE EVENTS
</span></caption>
<col align="left" width="57.133%">
<col align="left" width="22.867%">
<col align="left" width="20.000%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">ADVERSE EVENTS</span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">MDAH (N=101)</span></td>
<td class="Botrule" align="left" valign="top"><span class="Bold">SWOG (N=32)</span></td>
</tr>
<tr>
<td align="left" valign="top">ANY ADVERSE EVENT
</td>
<td align="left" valign="top">88%
</td>
<td align="left" valign="top">91%
</td>
</tr>
<tr>
<td align="left" valign="top">BODY AS A WHOLE
</td>
<td align="left" valign="top">72
</td>
<td align="left" valign="top">84
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">FEVER</span>
</td>
<td align="left" valign="top">60
</td>
<td align="left" valign="top">69
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">CHILLS</span>
</td>
<td align="left" valign="top">11
</td>
<td align="left" valign="top">19
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">FATIGUE</span>
</td>
<td align="left" valign="top">10
</td>
<td align="left" valign="top">38
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTION</span>
</td>
<td align="left" valign="top">33
</td>
<td align="left" valign="top">44
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">PAIN</span>
</td>
<td align="left" valign="top">20
</td>
<td align="left" valign="top">22
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">MALAISE</span>
</td>
<td align="left" valign="top">8
</td>
<td align="left" valign="top">6
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">DIAPHORESIS</span>
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">13
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">ALOPECIA</span>
</td>
<td align="left" valign="top">0
</td>
<td align="left" valign="top">3
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">ANAPHYLAXIS</span>
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">HEMORRHAGE</span>
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">HYPERGLYCEMIA</span>
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">6
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">DEHYDRATION</span>
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">NEUROLOGICAL
</td>
<td align="left" valign="top">21
</td>
<td align="left" valign="top">69
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">WEAKNESS</span>
</td>
<td align="left" valign="top">9
</td>
<td align="left" valign="top">65
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">PARESTHESIA</span>
</td>
<td align="left" valign="top">4
</td>
<td align="left" valign="top">12
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">HEADACHE</span>
</td>
<td align="left" valign="top">3
</td>
<td align="left" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">VISUAL DISTURBANCE</span>
</td>
<td align="left" valign="top">3
</td>
<td align="left" valign="top">15
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">HEARING LOSS</span>
</td>
<td align="left" valign="top">2
</td>
<td align="left" valign="top">6
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">SLEEP DISORDER</span>
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">3
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span>
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4046815" conceptname="Dysdiadochokinesis">CEREBELLAR SYNDROME</span>
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">  IMPAIRED MENTATION
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">PULMONARY
</td>
<td align="left" valign="top">35
</td>
<td align="left" valign="top">69
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">COUGH</span>
</td>
<td align="left" valign="top">10
</td>
<td align="left" valign="top">44
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">PNEUMONIA</span>
</td>
<td align="left" valign="top">16
</td>
<td align="left" valign="top">22
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">DYSPNEA</span>
</td>
<td align="left" valign="top">9
</td>
<td align="left" valign="top">22
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">SINUSITIS</span>
</td>
<td align="left" valign="top">5
</td>
<td align="left" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">PHARYNGITIS</span>
</td>
<td align="left" valign="top">0
</td>
<td align="left" valign="top">9
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">UPPER RESPIRATORY INFECTION</span>
</td>
<td align="left" valign="top">2
</td>
<td align="left" valign="top">16
</td>
</tr>
<tr>
<td align="left" valign="top">  ALLERGIC <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">PNEUMONITIS</span>
</td>
<td align="left" valign="top">0
</td>
<td align="left" valign="top">6
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">EPISTAXIS</span>
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">HEMOPTYSIS</span>
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">6
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">BRONCHITIS</span>
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">HYPOXIA</span>
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">GASTROINTESTINAL
</td>
<td align="left" valign="top">46
</td>
<td align="left" valign="top">63
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">NAUSEA</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">VOMITING</span>
</td>
<td align="left" valign="top">36
</td>
<td align="left" valign="top">31
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">DIARRHEA</span>
</td>
<td align="left" valign="top">15
</td>
<td align="left" valign="top">13
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">ANOREXIA</span>
</td>
<td align="left" valign="top">7
</td>
<td align="left" valign="top">34
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">STOMATITIS</span>
</td>
<td align="left" valign="top">9
</td>
<td align="left" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">  GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span>
</td>
<td align="left" valign="top">3
</td>
<td align="left" valign="top">13
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">ESOPHAGITIS</span>
</td>
<td align="left" valign="top">3
</td>
<td align="left" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">MUCOSITIS</span>
</td>
<td align="left" valign="top">2
</td>
<td align="left" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">LIVER FAILURE</span>
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">  ABNORMAL LIVER FUNCTION TEST
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">3
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">CHOLELITHIASIS</span>
</td>
<td align="left" valign="top">0
</td>
<td align="left" valign="top">3
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">CONSTIPATION</span>
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">3
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">DYSPHAGIA</span>
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">CUTANEOUS
</td>
<td align="left" valign="top">17
</td>
<td align="left" valign="top">18
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">RASH</span>
</td>
<td align="left" valign="top">15
</td>
<td align="left" valign="top">15
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">PRURITUS</span>
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">3
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">SEBORRHEA</span>
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">GENITOURINARY
</td>
<td align="left" valign="top">12
</td>
<td align="left" valign="top">22
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">DYSURIA</span>
</td>
<td align="left" valign="top">4
</td>
<td align="left" valign="top">3
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4056621" conceptname="Recurrent urinary tract infection">URINARY INFECTION</span>
</td>
<td align="left" valign="top">2
</td>
<td align="left" valign="top">15
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">HEMATURIA</span>
</td>
<td align="left" valign="top">2
</td>
<td align="left" valign="top">3
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">RENAL FAILURE</span>
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">  ABNORMAL RENAL FUNCTION TEST
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">PROTEINURIA</span>
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">HESITANCY</span>
</td>
<td align="left" valign="top">0
</td>
<td align="left" valign="top">3
</td>
</tr>
<tr>
<td align="left" valign="top">CARDIOVASCULAR
</td>
<td align="left" valign="top">12
</td>
<td align="left" valign="top">38
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">EDEMA</span>
</td>
<td align="left" valign="top">8
</td>
<td align="left" valign="top">19
</td>
</tr>
<tr>
<td align="left" valign="top">  ANGINA
</td>
<td align="left" valign="top">0
</td>
<td align="left" valign="top">6
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span>
</td>
<td align="left" valign="top">0
</td>
<td align="left" valign="top">3
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">ARRHYTHMIA</span>
</td>
<td align="left" valign="top">0
</td>
<td align="left" valign="top">3
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">SUPRAVENTRICULAR TACHYCARDIA</span>
</td>
<td align="left" valign="top">0
</td>
<td align="left" valign="top">3
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">MYOCARDIAL INFARCTION</span>
</td>
<td align="left" valign="top">0
</td>
<td align="left" valign="top">3
</td>
</tr>
<tr>
<td align="left" valign="top">  DEEP <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">VENOUS THROMBOSIS</span>
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">3
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">PHLEBITIS</span>
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">3
</td>
</tr>
<tr>
<td align="left" valign="top">  TRANSIENT ISCHEMIC ATTACK
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4311963" conceptname="Aneurysm">ANEURYSM</span>
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">CEREBROVASCULAR ACCIDENT</span>
</td>
<td align="left" valign="top">0
</td>
<td align="left" valign="top">3
</td>
</tr>
<tr>
<td align="left" valign="top">MUSCULOSKELETAL
</td>
<td align="left" valign="top">7
</td>
<td align="left" valign="top">16
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">MYALGIA</span>
</td>
<td align="left" valign="top">4
</td>
<td align="left" valign="top">16
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">OSTEOPOROSIS</span>
</td>
<td align="left" valign="top">2
</td>
<td align="left" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">ARTHRALGIA</span>
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">0
</td>
</tr>
<tr class="Last">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">TUMOR LYSIS SYNDROME</span>
</td>
<td align="left" valign="top">1
</td>
<td align="left" valign="top">0
</td>
</tr>
</tbody>
</table>
<p>More than 3000 adult patients received fludarabine phosphate for injection in studies of other <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemias</span>, <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span>, and other <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>. The spectrum of adverse effects reported in these studies was consistent with the data presented above.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s46"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE
</h1>
<p class="First">High doses of fludarabine phosphate for injection (see <span class="Bold"><a href="#s11">WARNINGS</a></span> section) have been associated with an irreversible central nervous system toxicity characterized by delayed <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. High doses are also associated with severe <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> due to bone marrow suppression. There is no known specific antidote for fludarabine phosphate for injection overdosage. Treatment consists of drug discontinuation and supportive therapy.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s47"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s48"></a><a name="section-11.1"></a><p></p>
<h2>Usual Dose
</h2>
<p class="First">The recommended adult dose of fludarabine phosphate for injection is 25 mg/m<span class="Sup">2</span> administered intravenously over a period of approximately 30 minutes daily for five consecutive days. Each 5 day course of treatment should commence every 28 days. Dosage may be decreased or delayed based on evidence of hematologic or nonhematologic toxicity. Physicians should consider delaying or discontinuing the drug if <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> occurs.
</p>
<p>A number of clinical settings may predispose to increased toxicity from fludarabine phosphate for injection. These include advanced age, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and bone marrow impairment. Such patients should be monitored closely for excessive toxicity and the dose modified accordingly.
</p>
<p>The optimal duration of treatment has not been clearly established. It is recommended that three additional cycles of fludarabine phosphate for injection be administered following the achievement of a maximal response and then the drug should be discontinued.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s49"></a><a name="section-11.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">Adjustments to the starting dose are recommended to provide appropriate drug exposure in patients with creatinine clearance 30 to 79 mL/min, as estimated by the Cockroft-Gault equations. These adjustments are based on a pharmacokinetic study in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Fludarabine phosphate for injection should not be administered to patients with creatinine clearance less than 30 mL/min.
</p>
<a name="t301"></a><table width="100%">
<caption><span>Starting Dose Adjustment for <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</span></caption>
<col align="left" width="50.500%">
<col align="left" width="49.500%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Creatinine Clearance<br><br></span></th>
<th class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Starting Dose<br><br></span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="center" valign="top">≥ 80 mL/min<br><br>
</td>
<td class="Botrule Rrule" align="center" valign="top">25 mg/m<span class="Sup">2</span> (full dose)<br><br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">50 to 79 mL/min<br><br>
</td>
<td class="Botrule Rrule" align="center" valign="top">20 mg/m<span class="Sup">2
</span><br><br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">30 to 49 mL/min<br><br>
</td>
<td class="Botrule Rrule" align="center" valign="top">15 mg/m<span class="Sup">2
</span><br><br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">&lt; 30 mL/min<br><br>
</td>
<td class="Botrule Rrule" align="center" valign="top">do not administer <br><br>
</td>
</tr>
</tbody>
</table>
<p>Renally impaired patients should be monitored closely for excessive toxicity and the dose modified accordingly.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s50"></a><a name="section-11.3"></a><p></p>
<h2>Preparation of Solutions
</h2>
<p class="First">Fludarabine phosphate for injection should be prepared for parenteral use by aseptically adding Sterile Water for Injection, USP. When reconstituted with 2 mL of Sterile Water for Injection, USP, the solid cake should fully dissolve in 15 seconds or less; each mL of the resulting solution will contain 25 mg of fludarabine phosphate, 25 mg of mannitol, and sodium hydroxide to adjust the pH to 7.7. The pH range for the final product is 7.2 to 8.2. In clinical studies, the product has been diluted in 100 cc or 125 cc of 5% Dextrose Injection, USP or 0.9% Sodium Chloride, USP.
</p>
<p>Reconstituted fludarabine phosphate for injection contains no antimicrobial preservative and thus should be used within 8 hours of reconstitution. Care must be taken to assure the <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> of prepared solutions. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.
</p>
<p>Fludarabine phosphate for injection should not be mixed with other drugs.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s51"></a><a name="section-11.4"></a><p></p>
<h2>Handling and Disposal
</h2>
<p class="First">Procedures for proper handling and disposal should be considered. Consideration should be given to handling and disposal according to guidelines issued for cytotoxic drugs. Several guidelines on this subject have been published.<span class="Sup">1-4  </span></p>
<p>Caution should be exercised in the handling and preparation of fludarabine phosphate for injection solution. The use of latex gloves and safety glasses is recommended to avoid exposure in case of breakage of the vial or other accidental spillage. If the solution contacts the skin or mucous membranes, wash thoroughly with soap and water; rinse eyes thoroughly with plain water. Avoid exposure by inhalation or by direct contact of the skin or mucous membranes.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s52"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED
</h1>
<p class="First">Fludarabine Phosphate for Injection, USP is supplied as follows:
</p>
<table width="100%">
<col align="left" width="25.000%">
<col align="left" width="50.000%">
<col align="left" width="25.000%">
<tbody class="Headless">
<tr class="First">
<td align="justify" valign="top"><span class="Bold">NDC</span></td>
<td align="justify" valign="top"><span class="Bold">Fludarabine Phosphate for Injection, USP</span></td>
<td align="justify" valign="top"><span class="Bold">Package Factor</span></td>
</tr>
<tr class="Last">
<td align="justify" valign="top">25021-237-06
</td>
<td align="justify" valign="top">50 mg Single-Dose Vial
</td>
<td align="justify" valign="top">1 vial per carton
</td>
</tr>
</tbody>
</table>
<p>Fludarabine Phosphate for Injection, USP is supplied as a white, lyophilized solid cake. Each vial contains 50 mg of fludarabine phosphate, USP, 50 mg of mannitol, USP, and sodium hydroxide to adjust pH to 7.7. The pH range for the final product is 7.2 to 8.2.
</p>
<p>Fludarabine Phosphate for Injection, USP is supplied in a clear glass single dose vial (6 mL capacity) and packaged individually.
</p>
<div class="Section" data-sectionCode="44425-7">
<a name="s53"></a><a name="section-12.1"></a><p></p>
<h2>Storage Conditions
</h2>
<p class="First"><span class="Bold">Store refrigerated between 2° and 8°C (36° and 46°F).</span></p>
<p><span class="Bold">Sterile, Nonpyrogenic, Preservative-free.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="s54"></a><a name="section-13"></a><p></p>
<h1>REFERENCES
</h1>
<ol class="Arabic">
<li>Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings. NIOSH Alert 2004-165.
</li>
<li>OSHA Technical Manual, TED 1-0. 15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. <span class="Underline">http://www.osha.gov/dts/osta/otm/otm_vi_2.html</span>
</li>
<li>American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. <span class="Italics">Am J Health-Syst Pharm.</span> 2006: 63: 1172-1193.
</li>
<li>Polvich, M., White, J.M., &amp; Kelleher, L.O. (eds.) 2005. Chemotherapy and biotherapy guidelines and recommendations for practice (2<span class="Sup">nd</span> ed.). Pittsburgh, PA: Oncology Nursing Society
</li>
</ol>
<p class="First">SAGENT™
</p>
<p>Mfd. for SAGENT Pharmaceuticals<br>Schaumburg, IL 60195<br>Made in USA<br>©2014 Sagent Pharmaceuticals, Inc.
</p>
<p>October 2014
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s55"></a><a name="section-14"></a><p></p>
<p class="First">PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label
</p>
<p>NDC 25021-237-06
</p>
<p>Rx only
</p>
<p>FLUDARABINE PHOSPHATE
</p>
<p>FOR INJECTION, USP
</p>
<p>50 mg per vial
</p>
<p>Single-Dose Vial
</p>
<p>For Intravenous Use Only
</p>
<div class="Figure">
<a name="f02"></a><img alt="PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=763d6c6d-cfed-4813-8cc5-41e78d357845&amp;name=flu15-0000-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FLUDARABINE PHOSPHATE 		
					</strong><br><span class="contentTableReg">fludarabine phosphate injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:25021-237</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>fludarabine phosphate</strong> (fludarabine) </td>
<td class="formItem">fludarabine phosphate</td>
<td class="formItem">25 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:25021-237-06</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076349</td>
<td class="formItem">12/15/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Sagent Pharmaceuticals
							(796852890)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e2a4aec7-7ba5-4200-a1fe-77904e671ac8</div>
<div>Set id: 763d6c6d-cfed-4813-8cc5-41e78d357845</div>
<div>Version: 2</div>
<div>Effective Time: 20141030</div>
</div>
</div> <div class="DistributorName">Sagent Pharmaceuticals</div></p>
</body></html>
